1. % of the projects in development in the leading therapeutic areas were considered to have a novel mode of action
APRIL 2007
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your use of these materials is subject to the terms and conditions hereof. Please read the disclaimer carefully before using these materials.

2. % of the projects in development in the leading therapeutic areas were considered to have a novel mode of action
Chapter 8
Therapeutic Areas
Figure 8.6
Key message
Approximately 50-90% of the projects in development in the leading therapeutic areas are considered to have a novel mode of action; novelty was highest for anti-cancer and nervous system projects, and lowest for respiratory projects. This confirms that the industry continues to invest in novel approaches in areas of high unmet need.
Methodology
Presented is the proportion of active substances being developed for first launch in specific therapeutic areas that have an established mode of action versus a novel mode of action, based on an aggregate of the data provided by 24 companies in Active substances were allocated to therapeutic areas based on the indication under investigation using the World Health Organisation’s Anatomical Therapeutic Chemical (ATC) classification system. The analysis excludes active substances where mode of action was not provided.
Key Definitions
Mode of action: The pharmacological mechanism(s) by which the active substance interacts with macromolecular targets of the body, which modulates the function, or the rate of the function, of a physiological process. Targets may include, but are not limited to, receptors (for example hormones, growth factors or neurotransmitters), enzymes and ion channels etc.
CMR International Performance Metrics Programme / Source
Global R&D Performance Metrics Programme
This graph includes data from 24 companies providing information about the mode of action for five or more active substances in a given therapeutic area in development for first launch on 31st December n is the number of active substances being developed for first launch for which information relating to the mode of action was available.
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

3. Terms of Use and Disclaimer
The materials contained in these slides may be used for your own use in presenting at conferences and meetings or for inclusion in reports provided that you acknowledge the source of the materials and include the following statement: “2008 © Thomson Reuters. Some of the materials and/or data in this [report, presentation, paper etc] are reproduced under a license from Thomson Reuters. You may not copy or re-distribute these materials in whole or in part without the written consent of Thomson Reuters”.
Charts, graphs, and illustrations contained in these slides may not be decompiled, reverse engineered, or disassembled.
The copyright and other intellectual property rights in these slides is owned by Thomson Reuters or its licensors. Except for the license set out in these Terms of Use, Thomson Reuters neither assigns any rights nor grants any licenses or rights in respect of these slides to you and any use of these slides other than in accordance with these Terms of Use is subject to Thomson Reuters’ prior written consent. For additional permissions, please contact: [contact ]
THOMSON REUTERS MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS OR CORRECTNESS OF ANY MATERIALS CONTAINED WITHIN THESE SLIDES OR THAT ALL ERRORS IN THE SLIDES OR THE MATERIALS CONTAINED WITHIN THESE SLIDES WILL BE CORRECTED.
THOMSON REUTERS IS AN INFORMATION PROVIDER AND DOES NOT PROVIDE LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVICE. THE MATERIALS CONTAINED IN THESE SLIDES ARE FOR GENERAL INFORMATION PURPOSES ONLY, ARE NOT INTENDED TO CONSTITUTE LEGAL OR OTHER PROFESSIONAL ADVICE, AND SHOULD NOT BE RELIED ON OR TREATED AS A SUBSTITUTE FOR SPECIFIC ADVICE RELEVANT TO PARTICULAR CIRCUMSTANCES. THOMSON REUTERS SHALL NOT BE LIABLE FOR ANY LOSS THAT MAY ARISE FROM ANY RELIANCE BY YOU, YOUR EMPLOYER OR CLIENT, OR ANY OTHER THIRD PARTY, ON THE MATERIALS CONTAINED IN THESE SLIDES.
THOMSON REUTERS WILL NOT BE LIABLE IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSS OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OF USE OR YOUR USE OF THE SLIDES, HOWEVER SUCH INDIRECT LOSS OR DAMAGE MAY ARISE.
You shall not assign, sub-licence or delegate any of your rights or obligations under these Terms of Use without the prior written consent of Thomson Reuters; any assignment, sub-licensing or delegation in breach of these Terms of Use shall be null and void. If any provision of these Terms of Use are determined to be illegal or unenforceable by any court of competent jurisdiction it shall be deemed to have been deleted without affecting the remaining provisions. These Terms of Use will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. You hereby irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Philadelphia, PA, USA.